Dr. Milton Packer, a world-renowned cardiologist and congestive heart failure expert, has called for a fundamental change in the way we think of chronic disease: “…it is now critical for physicians to reconceptualize SGLT2 inhibitors (like Jardiance) as organ-protective agents rather than glucose-lowering drugs.” That same idea can be extended to lisinopril, losartan, statins, metformin, and eplerenone which also protect every organ and cell in the body while slowing aging. What do you current and future medical leaders think? How long will it take to start moving in this direction?
Natural occurring endogenous Beta-Hydroxybutyrate produced during fasting or ketogenic style eating may have a broad regulatory role in metabolic disease through alterations in histone acetylation and gene expression, post-translational protein function, and cell surface receptor activation. Endothelial cellular repairs may involve BHB. Stem cell activation may involve BHB, etc., etc., and etc. better than ALL these drugs, Bill.
Natural occurring endogenous Beta-Hydroxybutyrate produced during fasting or ketogenic style eating may have a broad regulatory role in metabolic disease through alterations in histone acetylation and gene expression, post-translational protein function, and cell surface receptor activation. Endothelial cellular repairs may involve BHB. Stem cell activation may involve BHB, etc., etc., and etc. better than ALL these drugs, Bill.